 |
39 Diseases |  |
32 Trials |
|
32 Trials |  |
385 News |  |
| 123456» |
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: The Effects of Human Chorionic Gonadotropin and Gonadotropin-Releasing Hormone Receptor Antagonist on Testicular Steroidogenesis in Normal and Obese Rats. (Pubmed Central) - Sep 22, 2024
Unlike control rats (normal diet), the expression of the luteinizing hormone receptor gene in these rats did not change in response to hCG stimulation and cetrorelix administration; they also showed a paradoxical, more pronounced response to hCG administration under conditions of suppression of the gonadotropin secretion by cetrorelix. This suggests that the etiology and pathogenesis of obesity may have different effects on the hormonal status of the male reproductive system.
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Development of an AI-based support system for controlled ovarian stimulation. (Pubmed Central) - Sep 3, 2024
The AI algorithm achieved high accuracy and was confirmed to be useful. The AI system has now been implemented as a COS tool in our clinical group for self-funded treatments.
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Smooth muscle electromyography for detecting major alterations in the estrus cycle in rats. (Pubmed Central) - Aug 8, 2024
The rats received a daily injection of cetrorelix acetate solution for 7 days, while another group served as the control...Fluorescence imaging showed high levels of uterine ?v?3 integrin during the proestrus-estrus phase, but inhibiting the sexual cycle reduced fluorescence activity. Based on the results, the SMEMG and IVIS imaging methods are suitable for detecting estrus phase alterations in rats.
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Influence of Replacing Soybean Meal with Nigella sativa Seed Meal on Feed Intake, Digestibility, Growth Performance, Blood Metabolites, and Antioxidant Activity of Growing Lambs. (Pubmed Central) - Jul 13, 2024
Higher economic efficiencies were observed with the NSM75 followed by NSM50 and then NSM100 treatments. It is concluded that replacing 75% of SBM with NSM enhanced feed conversion and economic efficiency.
- | Cetrotide (cetrorelix) / EMD Serono
Retrospective data, Journal, Real-world evidence, Real-world: Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study. (Pubmed Central) - Jul 1, 2024
Multivariate logistic regression analyses suggested that the type of GnRH antagonist did not independently impact the number of oocytes retrieved, usable embryos, good-quality embryos, moderate to severe OHSS rate, clinical pregnancy, miscarriage, or live birth rate. The retrospective analysis revealed no clinically significant differences in reproductive outcomes between Cetrotide
- | Orilissa (elagolix) / AbbVie
Journal: Elagolix Represents a Less Invasive and Cheaper Option than Injectable GnRH Antagonist for Ovulation Suppression in IVF. (Pubmed Central) - Mar 14, 2024
Oral GnRH antagonist, a much cheaper and less invasive medication that is used at a lower frequency, showed comparable ovulation suppression to the costly injectable GnRH antagonist. Further studies are required to evaluate the effect of oral GnRH antagonist on endometrial lining receptivity and pregnancy outcomes especially when using fresh embryo transfer IVF protocols.
- Cetrotide (cetrorelix) / EMD Serono
IN-VITRO FERTILIZATION INDUCED SEVERE ACUTE KIDNEY INJURY (SAT-213; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1481;
Early therapeutic interventions if not instituted properly could lead to mortality. The management of these patients entails hydration and albumin infusion.
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion date: Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (clinicaltrials.gov) - Mar 2, 2024
P=N/A, N=240, Completed, Sponsor: Shanghai First Maternity and Infant Hospital
The management of these patients entails hydration and albumin infusion. Trial completion date: Jul 2023 --> Feb 2024
- | Cetrotide (cetrorelix) / EMD Serono
Journal: A corn-fermented protein ingredient can be included in early nursey diets without compromising pig growth performance and health status. (Pubmed Central) - Feb 23, 2024
Pens were assigned to one of 4 dietary treatments: CON: a common nursery feeding program; SBM75: CON diet replacing 75% of soybean meal (SBM) with GDDY; FM/ESBM: CON diet without fish meal (FM) and enzyme-treated SBM (ESBM)?+?GDDY; GDDY50: CON diet replacing 50% of SBM, FM, and ESBM with GDDY...These results supported the hypothesis that GDDY can be incorporated in nursery pig diets during the first couple weeks after weaning without affecting growth performance. However, in the late nursery period, inclusion levels starting at 14% can compromise performance.
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: Effects of Cetrorelix on Ovary and Endometrium Prior to Anti-PD-L1 Antibody in Murine Model. (Pubmed Central) - Jan 30, 2024
Our study underscores the potential reproductive implications of cetrorelix treatment prior to Anti-PD-L1 therapy, shedding light on its short-term protective effects on the uterus. Further studies are necessary to understand long-term and clinical implications.
- | Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
Journal: Original delayed-start ovarian stimulation protocol with a gonadotropin-releasing hormone antagonist, medroxyprogesterone acetate, and high-dose gonadotropin for poor responders and patients with poor-quality embryos. (Pubmed Central) - Dec 3, 2023
They received cetrorelix acetate (3 mg) and MPA (10 mg) on cycle day 3, and high-dose gonadotropin was initiated on day 11. When the leading follicle reached 14
- || Cetrotide (cetrorelix) / EMD Serono
Review, Journal: Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle. (Pubmed Central) - Nov 30, 2023
Finally, MPA 10 mg suggests a lower OPCR than MPA 4 mg. There is uncertainty regarding the rest of the outcomes due to imprecision and no solid conclusions can be drawn.
- || Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company, Cetrotide (cetrorelix) / EMD Serono, Mifeprex (mifepristone) / Danco Laboratories
Review, Journal: Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids. (Pubmed Central) - Nov 21, 2023
Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules.
- || Mifeprex (mifepristone) / Danco Laboratories
Clinical, Journal: Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial. (Pubmed Central) - Oct 22, 2023
There was no significant difference in cumulative live birth rates (LBRs) between the combination and mifepristone group (74.4% vs. 76.9%). The combination treatment effectively reduces the incidence of moderate/severe OHSS in high-risk women.
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion, Trial completion date, Trial primary completion date: Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (clinicaltrials.gov) - Sep 7, 2023
P=N/A, N=240, Completed, Sponsor: Shanghai First Maternity and Infant Hospital
The combination treatment effectively reduces the incidence of moderate/severe OHSS in high-risk women. Not yet recruiting --> Completed | Trial completion date: Feb 2023 --> Jul 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
- | Cetrotide (cetrorelix) / EMD Serono
New trial, Head-to-Head: Effectiveness of Biosimilar Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone Antagonist Protocol in Women Undergoing IVF (clinicaltrials.gov) - Sep 5, 2023
P=N/A, N=1338, Not yet recruiting, Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi
- ||| Yselty (linzagolix) / Kissei, Theramex, Syneos Health, Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial initiation date, Trial primary completion date: Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures (clinicaltrials.gov) - Jul 28, 2023
P2, N=240, Not yet recruiting, Sponsor: Bio Genuine (Shanghai) Biotech Co., Ltd.
Not yet recruiting --> Completed | Trial completion date: Feb 2023 --> Jul 2023 | Trial primary completion date: Aug 2022 --> Mar 2023 Trial completion date: Jul 2024 --> Dec 2024 | Initiation date: Feb 2023 --> Aug 2023 | Trial primary completion date: Dec 2023 --> Jun 2024
- | progesterone / Generic mfg.
New P2/3 trial: Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization (clinicaltrials.gov) - Jul 20, 2023
P2/3, N=200, Not yet recruiting, Sponsor: Beni-Suef University
- | progesterone / Generic mfg.
New trial: Progesterone-Primed Ovarian Simulation in Controlled-ovarian Simulation of Infertile PCOS Patients (clinicaltrials.gov) - Jul 12, 2023
P=N/A, N=238, Completed, Sponsor: Zagazig University
- | Cetrotide (cetrorelix) / EMD Serono
Enrollment open, Trial completion date, Trial primary completion date: Acupuncture in the Freeze-all IVF Cycle (clinicaltrials.gov) - May 31, 2023
P=N/A, N=90, Recruiting, Sponsor: Peking University Third Hospital
Trial completion date: Jul 2024 --> Dec 2024 | Initiation date: Feb 2023 --> Aug 2023 | Trial primary completion date: Dec 2023 --> Jun 2024 Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Cetrorelix in reproductive medicine. (Pubmed Central) - May 24, 2023
After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol.
- | letrozole / Generic mfg.
Trial completion, Trial completion date: Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) - May 10, 2023
P3, N=900, Completed, Sponsor: The University of Hong Kong
The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol. Recruiting --> Completed | Trial completion date: Oct 2023 --> Apr 2023
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring, Cetrotide (cetrorelix) / EMD Serono
Trial completion, Phase classification, Trial completion date: CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) - May 9, 2023
P1/2, N=200, Completed, Sponsor: Lebanese University
Recruiting --> Completed | Trial completion date: Oct 2023 --> Apr 2023 Active, not recruiting --> Completed | Phase classification: PN/A --> P1/2 | Trial completion date: Dec 2021 --> May 2023
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Characterization by LC-MS/MS of oxidized products identified in synthetic peptide somatostatin and cetrorelix submitted to forced oxidative stress by hydrogen peroxide: Two case studies. (Pubmed Central) - May 7, 2023
Identification and quantification of oxidized species were achieved by high-resolution MS and MS/MS experiments. Thus, FDSs undoubtedly aid the evaluation of the CQAs as an important component of the characterization package as recommended by HAs and ICH, facilitating the understanding of unforeseen features of the studied molecule used as drugs.
- | progesterone / Generic mfg.
New trial: Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patient (clinicaltrials.gov) - May 6, 2023
P=N/A, N=210, Not yet recruiting, Sponsor: Fayoum University
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A (clinicaltrials.gov) - Apr 25, 2023
P3, N=204, Not yet recruiting, Sponsor: ShangHai Ji Ai Genetics & IVF Institute
Thus, FDSs undoubtedly aid the evaluation of the CQAs as an important component of the characterization package as recommended by HAs and ICH, facilitating the understanding of unforeseen features of the studied molecule used as drugs. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (clinicaltrials.gov) - Apr 25, 2023
P=N/A, N=784, Recruiting, Sponsor: ShangHai Ji Ai Genetics & IVF Institute
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2022 --> Sep 2024
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Combination treatment of recombinant growth differentiation factor-9 and Cetrorelix improves gestational origin of the polycystic ovarian syndrome in female rats. (Pubmed Central) - Apr 11, 2023
In conclusion, rGDF-9 could be a potential therapeutic agent in combination with Cetrorelix as a better treatment regime for metabolic and reproductive phenotypes in PCOS. However, the effect of rGDF-9 on infertility-associated phenotypes in PCOS needs further evaluation.
- Cetrotide (cetrorelix) / EMD Serono
INHIBITION OF THE GNRH/GNRHR1 AXIS AMELIORATES THE PHENOTYPES OF PRIMARY BILIARY CHOLANGITIS (PBC). (S403 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_4237;
We demonstrated enhanced expression of the GnRH/GnRHR1 axis in mouse PBC models and late-stage PBC samples. Inhibition of GnRHR1 with Cetrorelix may be an important target for the management of PBC phenotypes.
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds. (Pubmed Central) - Jan 12, 2023
These enzymes could, in principle, activate the amide bond via reductive or oxidative metabolism outside the amide bond. The identity of the involved drug metabolizing enzymes in this process is still unknown.
- || Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
Retrospective data, Review, Journal: What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis. (Pubmed Central) - Jan 4, 2023
More trials are required to assess the comparative effectiveness of ganirelix versus cetrorelix, the effect of different pretreatment interventions (e.g. progestins or oestradiol) or the effect of different criteria for initiation of the antagonist in the flexible protocol. Furthermore, more studies are required examining the optimal GnRH antagonist protocol in women with high or low response to ovarian stimulation.
- ||| Cetrotide (cetrorelix) / EMD Serono
Clinical: Lucky patient with healthy long enough small bowel and colon. SB 75< cm survives with a colon. This case I'd resect the dead 100 cm and make an anastomosis. Certainly heparinize and do an angiography if any vascular intervention is needed. For long term plan, what's the etiology? (Twitter) - Dec 22, 2022
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Mechanism of LH release after peripheral administration of kisspeptin in cattle. (Pubmed Central) - Dec 3, 2022
Results support the hypothesis that the effect of peripheral kisspeptin is mediated downstream of GnRH synthesis and does not involve GnRH-independent LH release from gonadotrophs. Peripheral kisspeptin may release pre-synthesized GnRH from the nerve terminals in areas outside the blood-brain barrier.
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A (clinicaltrials.gov) - Nov 29, 2022
P3, N=400, Recruiting, Sponsor: ShangHai Ji Ai Genetics & IVF Institute
Peripheral kisspeptin may release pre-synthesized GnRH from the nerve terminals in areas outside the blood-brain barrier. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Dec 2023
- | progesterone / Generic mfg.
Journal: Comparing Progesterone Primed Ovarian Stimulation (PPOS) to GnRH Antagonist Protocol in Oocyte Donation Cycles. (Pubmed Central) - Nov 8, 2022
5945.86 ± 2848.59, respectively, P < 0.001). Our study identifies PPOS protocol using MPA to be more cost-effective and patient-friendly than conventional GnRH antagonist protocol in oocyte donor cycles.
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: The in vitro effect of gonadotropin-releasing hormones, GnRH-I and GnRH-II, on the motility, vitality, and acrosome integrity of Vervet monkey (Chlorocebus aethiops) spermatozoa. (Pubmed Central) - Nov 3, 2022
Additionally, a GnRHR-I antagonist (GnRHR-A), Cetrorelix, was tested to establish its antagonistic capability on GnRH...While GnRH-I or GnRH-II at low dose concentrations resulted in in vitro inhibition of sperm motility, it appears to have no adverse effects on other sperm functional parameters evaluated. These collective observations possibly indicate an essential role for GnRH in the in vivo process of sperm selection in the female reproductive tract.
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage 'in mice. (Pubmed Central) - Oct 14, 2022
Pretreatment with GnRH antagonist transiently reduced testicular weight, epididymal weight, germinal proliferation and sperm count; it also abolished the permanent long-term effect of CTX on these parameters and prevented cyclophosphamide-induced testicular toxicity characterized by apoptosis and serum AMH increase and irreversible loss of spermatogonial reserve. Our findings imply that pretreatment with GnRH antagonist temporarily reduces spermatogenesis and may be used as pretreatment for reducing chemotherapeutic testicular toxicity.
- | Cetrotide (cetrorelix) / EMD Serono
New trial: DYG Versus Cetrorelix in Oocyte Donation (clinicaltrials.gov) - Oct 13, 2022
P=N/A, N=202, Completed, Sponsor: Clinica de la Mujer Medicina Reproductiva, Chile
- | Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol (clinicaltrials.gov) - Sep 30, 2022
P=N/A, N=142, Recruiting, Sponsor: Northwell Health
Our findings imply that pretreatment with GnRH antagonist temporarily reduces spermatogenesis and may be used as pretreatment for reducing chemotherapeutic testicular toxicity. Trial completion date: Jun 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
- | Yselty (linzagolix) / Kissei, Theramex, Syneos Health
Journal: Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors. (Pubmed Central) - Sep 10, 2022
Furthermore, all animals presenting arrested menstrual cycles following linzagolix treatment showed recovery of hormone secretion and regular menstrual cycles after administration periods ended. Our results demonstrated that linzagolix has potential as a novel agent for reproductive-aged women suffering from sex hormone-dependent diseases.
- progesterone / Generic mfg.
PROGESTERONE PRIMED OVARIAN STIMULATION PROTOCOL (PPOS) VS GNRH ANTAGONIST FOR PATIENTS OF FREEZE ALL CYCLES: A PROSPECTIVE RANDOMISED CONTROLLED TRIAL (Anaheim Convention Center - Poster Hall in Expo Hall) - Aug 21, 2022 - Abstract #ASRM2022ASRM_1126;
Hence, PPOS with MPA seems to be a patient friendly and cost effective choice for women undergoing ovarian stimulation without affecting oocyte quality. IMPACT STATEMENT: Progestins can adequately prevent premature ovulation in ART cycles, with the additional benefit of having no OHSS .
- Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
A STUDY TO DETERMINE THE IMPACT OF DIMINISHED OOCYTE RESERVE (DOR) ON PREGNANCY OUTCOME IN WOMEN OF ADVANCED REPRODUCTIVE AGE (Anaheim Convention Center - Poster Hall in Expo Hall) - Aug 21, 2022 - Abstract #ASRM2022ASRM_807;
IMPACT STATEMENT: Some IVF centers may be willing to perform the procedure in women 40-42 as long as their serum AMH is normal. When the serum AMH is low they may be only willing to talk about the donor egg program.
- Cetrotide (cetrorelix) / EMD Serono
DOSE DEPENDENT INFLUENCE OF OVULATION INHIBITOR, CHLORMADINONE ACETATE OR CETRORELIX ON OOCYTE MATURATION IN NORMAL OVARIAN RESERVE PATIENTS: A RETROSPECTIVE STUDY WITH POISSON REGRESSION ANALYSIS (Anaheim Convention Center - 304AB) - Aug 21, 2022 - Abstract #ASRM2022ASRM_554;
In this population, no dose-dependent influence of CMA or cetrorelix on either oocyte maturation or fertilization rate in normal ovarian reserve patients was observed. IMPACT STATEMENT: In PPOS or GnRH-ant protocol, dosage of ovulation inhibitors was not associated with maturation and fertilization of oocytes.
- || Cetrotide (cetrorelix) / EMD Serono
FDA event: $AKRX Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg https://t.co/Ntzk3GJOJQ (Twitter) - Aug 16, 2022
- | progesterone / Generic mfg.
Preclinical, Retrospective data, Journal: Serum progesterone on the day of human chorionic gonadotropin (hCG) trigger as a predictor of in-vitro fertilization (IVF) outcome - a retrospective analysis of seven years. (Pubmed Central) - Aug 3, 2022
Having an elevated serum progesterone level on the day of hCG trigger was associated with lower pregnancy rates, but this is still not a robust marker to predict live births. More good quality evidence is needed.
- | Cetrotide (cetrorelix) / EMD Serono
Enrollment change, Trial termination: PPOS-Antagonis: Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol for Freeze-all Cycles (clinicaltrials.gov) - Jun 15, 2022
P=N/A, N=56, Terminated, Sponsor: Ibn Sina Hospital
More good quality evidence is needed. N=2000 --> 56 | Recruiting --> Terminated; Due to COVID19 Pandemic effect on 2020.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Ephedra herb reduces adriamycin-induced testicular toxicity by upregulating the gonadotropin-releasing hormone signalling pathway. (Pubmed Central) - Jun 8, 2022
In vitro, HEPH, ephedrine, and pseudoephedrine significantly reduced adriamycin-induced GC-1 cell apoptosis and reactive oxygen species levels and increased the expression of GnRH signalling pathway- and meiosis-related proteins. The effect of pseudoephedrine was greater than that of ephedrine, and these findings may be an important basis for understanding the effects of HEPH.
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles. (Pubmed Central) - May 29, 2022
It is easy to use, widely available and cost-effective. It may establish a new regimen of ovarian stimulation using MPA as an oral alternative to GnRH antagonist treatment in hyper-responders.
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Assessment of the Ovulation Inducing Activity of Extract and Various Solvent Fractions of Caralluma dalzieliiN E Brown. (Pubmed Central) - May 14, 2022
The result showed that Caralluma dalzielii extract and fractions possess ovulation inducing activity. Bioactive compounds could be isolated from both EAF and PEF which showed the highest ovulation inducing activity.
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome. (Pubmed Central) - Apr 23, 2022
Bioactive compounds could be isolated from both EAF and PEF which showed the highest ovulation inducing activity. Calcium gluconate treatment is not effective in the prevention of OHSS.